Author Archives: admin


Misplaced Assumptions, Where Investments Go Wrong – Seeking Alpha

You've heard the one about the physicist, chemist, and economist marooned on a desert island with a can of beans but no way to open it. With index finger on temple, the physicist opines, "Focus sunlight on the can to melt it." "No", the chemist interrupts, "We should pour saltwater on the lid to rust the can." The economist, matter-of-factly, ties off the debate, "Assume we have a can opener."

Richard Mason and Ian Mitroff might have called being stranded with no way to get at food in one's possession an "ill-structured" or "wicked problem". They would have encouraged the three academics to engage in some, "strategic assumption surfacing and testing" to:

Notice my insertion in brackets above, "[investment hypotheses]". In considering and revisiting such decisions, I repeatedly attempt to apply this technique to expose and evaluate strategic assumptions that may affect our results.

Not infrequently, revelation about assumptions comes to me after I have already moved forward with an investment. For example, a couple of years ago I made beefy bets on three CRISPR (gene editing) stocks following their IPO's - CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA). We did very well on them but sold out because I felt they had gotten ahead of themselves although I wasn't entirely sure why.

Something was niggling me that I couldn't quite explain. While walking our daughter's Yorkie a few months later, I ran into a friend who is very learned in stem cells. I mentioned backing away from our gene editing investments wondering out loud how most people could afford such treatments.

"Henry", he looked at me, "This is an issue. Other than through early-stage research grants, patients must tap private resources or look to foundations." Disappointingly, my friend's expert opinion seemed to confirm that funding, at least for now, is a limiting factor in how far and fast gene editing stocks can grow. I felt I had made a good decision to sell and move on. At a level, Bayer (OTCPK:BAYRY) must agree because they just backed off their original position in CRISPR Therapeutics. Strategic assumption testing.

However, that conversation didn't turn me away from all medical treatments; far from it. I later added to our position in Merck (MRK) that continues to receive approvals from governments around the world for the use of Keytruda to fight various cancers, bladder, Hodgkin lymphoma, neck, melanoma, pancreatic, small cell lung, and urothelial carcinoma among them. The strategic assumption here being, more applications x more government approvals = more revenue = more income = higher stock price and dividends.

And, although the word "genetics" is in its name, as opposed to one-patient-at-a-time editing, I also recently bought into NewLink Genetics (NLNK) that is discovering, developing, and commercializing medicines that tap the body's own immune system to fight disease. It was NewLink that discovered and then licensed to Merck, a 100%-effective Ebola vaccine that was recently approved by the FDA. It is NewLink that is now partnering with Ellipses Pharma, a UK private limited company, on an ovarian cancer treatment (that Merck does not have; hmmm). If approved, it could catapult NLNK to much higher levels. Although NewLink is still losing money, its balance sheet is pristine; it's positioned for growth. And, intangibly, I like the fact that it is headquartered in the heartland, Ames, Iowa; smart, hard-working people there.

Therefore, while on the one hand, patient-by-patient genetic treatments are overwhelmingly important, my current assumption is that they are not there yet from a shareholder perspective. On the other hand, using therapies - mono and poly - to fight cancer seems to be mushrooming.

Before moving on, it's also worth challenging assumptions about the very definition of healthcare. For example, with regularity, apps and gadgets are introduced to monitor bodily functions and wellness. Fitbit (FIT), that is in the process of being acquired by Alphabet (GOOG) (GOOGL), is a notable case in point.

Indeed, Alphabet is also perfecting an AI-based system that, in most cases, improves the accuracy of breast cancer diagnosis. In addition to benefiting those at risk, this technology may lower the need for less accurate technicians and doctors. Let us not forget that clinics and hospitals are businesses and, that here in US at least, the war rages over the cost of healthcare.

And, at an even broader level, Alphabet appears to be setting its sights on becoming a leader in medical diagnostics. If ever there was an indication of this, it is in the Mayo Clinic's recent announcement that they are teaming with Google on cloud-based data mining and AI to improve healthcare. This is a big deal that could recalibrate some basic assumptions in the field.

In a completely different category of investments, many SA contributors and commenters apparently still embrace the assumption that the sun still rises for Tanger Factory Outlets (SKT) and Simon Property Group (SPG). Here, obvious limiting factors are suppressed, talked over, or tuned out - the competitive domination of on-line shopping, big-box retailing, remote fulfillment, etc. For example, this research available for purchase from Coresight (I have no relationship with them) reports that: a) e-commerce is relentlessly gaining market share at an accelerating pace, b) there is no letup in the growth of retail defaults and bankruptcies, and c) disappointment will continue as new stores open into a flat sales environment (and, with interest/cap rates perhaps on the march again). For retail REIT pundits and investors to believe that they will beat these odds defies Einstein's very definition of insanity:

"doing the same thing over and over again expecting different results."

Tanger and Simon are classic "hole-in-your-pocket investments" wherein most investors blithely put those dividends in their tattered Levi's (NYSE:LEVI) and walk on not realizing that they've fallen through. This can be easily and conclusively demonstrated by adding up those dividends over time and subtracting the corresponding loss in these REITs' market caps. The algorithm is such: a) Pick a medium-term timeframe; I'll use 3 years, b) Add up all the dividends paid by the Simon Property Group and Tanger Factory Outlet during that time, and c) Subtract the difference in before versus after market cap. Material amounts of shareholder value have been destroyed:

Moreover, open the SKT and SPG pages on SA, and scroll down the sentiment summaries to the left and you will see that most contributors going back are skewed toward the bullish side of neutral; some are still "very bullish" notwithstanding years of disappointment during which they were also very bullish; is your head spinning?

For those investors looking for a "tell" on when REIT experts may be coming to grips with their own misplaced strategic assumptions, you need to look no further than to those who have shifted from recommending common to recommending preferred stock as it has been for: CBL Properties (CBL), Pennsylvania Real Estate (PEI), and Washington Prime Group (WPG). Definitionally, the destruction in shareholder value is seen in common stock prices. However, it is usually triggered farther up the balance sheet as I know from my days predicting REIT bankruptcies by anticipating covenant defaults.

And, for mall REIT investors who want to know who is picking up that money falling through the hole in your pocket, look no further than to compare the stock performance of SKT and SPG to, say, Alibaba (BABA), Amazon (AMZN), Target (TGT), and Walmart (WMT). There is a reason these lines inversely correlate:

Or, take those of us who write about the relative (de)merits of internal combustion, battery electric, and fuel cell engines. With every post, we confront assumptions involving limiting factors. ICE vehicles must be phased out given that their emissions are sickening planet earth; they are. BEV growth assumes the unconstrained availability of heavy metals essential to their production. FC(E)V power coming from natural gas is not carbon-free.

Have we pushed strategic assumption surfacing and testing far enough in this space? If you listen to Elon Musk, there is nothing more to debate; BEV's and, specifically, his BEV's are it. For us mortals, as opposed to driving a single stake in the ground, it may be wiser to spread out over various forward-looking investments including, for me: a) Toyota (TM) that continues to innovate around diversified product line that will increasingly deemphasize ICE vehicles in favor of hybrids, pure BEV, and FCV's, b) Suzuki (OTCPK:SZKMY) that commands a major share in the world's third largest automobile market, India, and is well positioned with low-energy-consumption scooters and motorcycles best suited for use in densely populated cities and poorer countries, and c) ABB (ABB) and Ballard (BLDP) that are focused on bringing clean(er) energy to commercial vehicles including boats and ships; others are, as well.

Strategic assumption testing has also brought us to investing in miners of heavy metals that are essential to all manufacturers of batteries and cleaner ICE vehicles - Amplats (OTCPK:ANGPY), Glencore (OTCPK:GLNCY), Norilsk (OTCPK:NILSY), South32 (OTCPK:SOUHY), Sumitomo Metals (OTCPK:SMMYY) - platinum, palladium, rhodium, cobalt, nickel, and manganese. To reemphasize, for now we simply don't accept as fact that there is only one right way to invest in clean energy vehicles.

For the climate change / global warming deniers out there, the time has come to embrace the strategic assumption that the transformation to clean, renewable, sustainable energy is happening. If you don't believe me, no offense taken. Believe the largest institutional investors and fund managers on earth - like Norway's sovereign wealth management fund, or BlackRock (BLK) whose Chairman and CEO, Larry Fink. If you as an individual investor assume that you can successfully buck this movement, you assume wrong. Do yourself, your children, and the rest of us a favor - get on board.

Strategic assumption - many individuals own too many high-priced, underutilized, fixed assets whether second homes, automobiles, airplanes, or boats. Businesses figured out long ago that they need to better utilize real estate and equipment, two of the costliest factors of production. A trend developed in renting vs. owning as, for example, when farmers began resisting the temptation to buy that expensive combine in favor of outsourcing harvesting to a neighbor who wanted better utilization of the expensive combine he already owned. Makes sense.

Expedia (EXPE) through HomeAway/VRBO, and Airbnb (private) have begun to address the challenge of underused residential real estate by bringing vacation property owners together with those who have no interest in title but instead rather rent for a week, a month, or a season. I am no longer able to count the number of our friends who use one of these options to escape winters or summers to friendlier climes in America's playgrounds. A while back, competing hotels felt the squeeze such that they too got into the vacation rental business; deals are everywhere.

And, we have a parallel situation with automobiles. I'm talking about Uber Technologies (UBER) and Lyft, Inc. (LYFT) where owners with time on their hands are, in effect, renting out their cars and driving services. For "renters", the equation could make sense if you're comfortable with rising prices, lax pick-up service, or the probability of jumping into a car with a pervert. The model may also work for "the middlemen" - Uber and Lyft - and any other company who can develop the critical mass while steering clear of existential liability.

But the strategic assumption that keeps getting in my way is from the vantage point of the supply-side, the owners. Specifically, I wonder if every-day individuals who are long fixed assets really understand their total cost of ownership or if they are just trying to earn some pin money or cover some bills. Mind you, there is nothing wrong with that unless/until one starts focusing return on their investment (and labor). Depreciation, licensing fees, insurance premiums, deductibles, fuel costs, maintenance expenses, tax and tax prep all add up never mind waking up to discover that one is earning well less than minimum wage on all the time and hassle associated with operating and administering such assets and activities.

Wrap it all together and I'm hung up on the assumption that EXPE, UBER and LYFT are limited-life alpha investments that owe their existence to 'temporary' albeit rolling excesses. As a board member our HOA, I'm channeling on a neighbor who last year whined about all the costs associated with his three homes. When I said to him, "Your problem is that you have too many damn homes", his surprise instantly turned to laughter and then agreement (a few months later he sold one of his places).

The chart below suggests that Uber, and Lyft have quickly moved through the growth phase of their S-curves and are now more-or-less mature investments that may tip into decline as others compete for market share. Indeed, they appear to have been mature investments before their IPO's hit the market; strange, isn't it.

Mason, Mitroff, and others would say that strategic assumption testing can/should be applied in "dialectic discourse" to planning [and investing]. A fancy phrase for a simple concept in which two or more people holding different points of view about a subject wish to establish the truth through reasoned arguments. The approach resembles debate but excludes subjective elements such as emotional appeal and pejorative rhetoric.

Dialectic discourse is difficult to achieve where emotions run high protected by ideological worldviews - the ethics of gene editing, ancestral comfort with tangible property / real estate, defensiveness that we humans contribute to climate change, and so forth. Those of us who write on these topics at times face numbing bias in the form or trite accolades by sycophants, or incoherent criticism by haters. To some extent, SA's anonymous format obstructs dialectic discourse.

So, when the process isn't possible, we're left to our own devices. To this I say, there is nothing wrong with having a conversation with yourself starting with basic questions: a) Am I open or closed minded; am I boxing myself in?, b) How might I think about challenges differently?, c) What other (substitute) options are available?, d) Could 'the answer' be different in the short versus long-run?, e) Do I know what I don't know; how do I find out? Repeat.

Does dialectic discourse work even if only with oneself? I'm careful to think that it might. I've followed up with alpha-level evidence on many of my own articles and a review of portfolio performance confirms that we are handily beating the indexes including the S&P 500 (as well as Warren Buffett's Berkshire Class A (BRK.A) shares). Because investment challenges these days are ill-structured / wicked, I recommend strategic assumption testing.

Disclosure: I am/we are long BAYRY, MRK, NLNK, GOOGL, BABA, TM, SZKMY, ABB, BLDP, ANGPY, GLNCY, NILSY, SOUHY, SMMYY. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Always do your own due diligence in consultation with a licensed and competent financial adviser who understands your unique needs and puts your interests ahead of their own. Remember, there are added considerations in owning foreign securities including those associated with ADR sponsorship, buying and selling the pinks, foreign withholding taxes on dividends, and fees. (All my proceeds from contributing to SA go to charity.)

See more here:
Misplaced Assumptions, Where Investments Go Wrong - Seeking Alpha

Stem Cell Banking Market smart Strategies of the Research and Development Process Dagoretti News – Dagoretti News

Stem cell banking or preservation is a combined process of extraction, processing and storage of stem cells, so that they may be used for treatment of various medical conditions in the future, when required. Stem cells have the amazing power to get transformed into any tissue or organ in the body. In recent days, stem cells are used to treat variety of life-threatening diseases such as blood and bone marrow diseases, blood cancers, and immune disorders among others.

The market of stem cell banking is anticipated to grow with a significant rate in the coming years, owing to factors such as, development of novel technologies for stem cell preservation and processing, and storage; growing awareness on the potential of stem cells for various therapeutic conditions. Moreover, increasing investments in stem cell research is also expected to propel the growth of the stem cell banking market across the globe. On other hand rising burden of major diseases and emerging economies are expected to offer significant growth opportunities for the players operating in stem cell banking market.

Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPBT00002082/

The key players influencing the market are:

Cordlife, ViaCord (A Subsidiary of PerkinElmer), Cryo-Save AG, StemCyte India Therapeutics Pvt. Ltd., Cryo-Cell International, Inc., SMART CELLS PLUS, Vita 34, LifeCell, Global Cord Blood Corporation, CBR Systems, Inc.

This report contains:

The global stem cell banking market is segmented on the basis of source, service type, and application. The source segment includes, placental stem cells (PSCS), dental pulp-derived stem cells (DPSCS), bone marrow-derived stem cells (BMSCS), adipose tissue-derived stem cells (ADSCS), human embryo-derived stem cells (HESCS), and other stem cell sources. Based on service type the market is segmented into, sample processing, sample analysis, sample preservation and storage, sample collection and transportation. Based on application, the market is segmented as, clinical applications, research applications, and personalized banking applications.

Stem Cell Banking Market Global Analysis to 2027 is an expert compiled study which provides a holistic view of the market covering current trends and future scope with respect to product/service, the report also covers competitive analysis to understand the presence of key vendors in the companies by analyzing their product/services, key financial facts, details SWOT analysis and key development in last three years. Further chapter such as industry landscape and competitive landscape provides the reader with recent company level insights covering mergers and acquisitions, joint ventures, collaborations, new product developments/strategies taking place across the ecosystem. The chapters also evaluate the key vendors by mapping all the relevant products and services to exhibit the ranking/ position of top 5 key vendors.

Stem Cell Banking Market is a combination of qualitative as well as quantitative analysis which can be broken down into 40% and 60% respectively. Market estimation and forecasts are presented in the report for the overall global market from 2018 2027, considering 2018 as the base year and 2018 2027 forecast period. Global estimation is further broken down by segments and geographies such as North America, Europe, Asia-Pacific, Middle East & Africa and South America covering major 16 countries across the mentioned regions. The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market.

Report Spotlights

Purchase This Report @ https://www.theinsightpartners.com/buy/TIPBT00002082/

About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

See the article here:
Stem Cell Banking Market smart Strategies of the Research and Development Process Dagoretti News - Dagoretti News

Meet the Culprits of Cell Culture Contamination – Technology Networks

The air is warm and humid, there is an abundance of food, and your friends come and go with their shiny toys. What sounds like a dreamy summer holiday is also the reality of in vitro cell culture experiments, and a golden opportunity for contaminants to intrude. Every person, reagent, and piece of equipment in the laboratory is a potential vehicle for invasive microbes, unwelcome cells and chemical impurities, which can create costly issues in both bench research and manufacturing. Cell culture contamination is a problem on many levels, creating immediate implications for experiments and wider issues for the scientific community.Consequences of cell culture contaminationContaminants can affect all cell characteristics (e.g. growth, metabolism, and morphology) and contribute to unreliable or erroneous experimental results. Cell culture contamination will likely create a need for experiments to be repeated, resulting in frustrating time delays and costly reagent wastage. Data derived from undetected contaminated cultures can end up published in scientific journals, allowing others to build hypotheses from dubious results. The pervasiveness of cross-contaminated and misidentified cell lines is a decades-long issue; in 1967, cell lines thought to be derived from various tissues were shown to be HeLa cells, a human cervical adenocarcinoma cell line.1 However, studies involving these misidentified cell lines continued to feature in hundreds of citations during the early 2000s.2This pattern is a well-acknowledged problem and threatens to undermine scientific integrity. The first published retraction in Nature Methods was due to cell line contamination3, and one conservative estimate of contaminated literature in 2017 found 32,755 articles reporting on research with misidentified cells.4 While many scientists may have been blissfully ignorant in the past, awareness of misidentified cell lines is growing.Deciding how best to deal with this knowledge is not straightforward and has been discussed extensively.4 In the interest of preventing further data contamination, a certificate of authentication of the origin and identity of human cells is now required by the International Journal of Cancer, and encouraged by funding agencies. Others have questioned whether mandatory testing really is the best way forward.3But what should be done about existing contaminated literature? Mass retraction of affected articles may disproportionately punish the careers of a few scientists, and could be a waste of resources containing potentially valuable data. One recently proposed system of self-retraction recommends replacing blame with praise in order to encourage self-correction.5 Post hoc labeling of published articles in the form of an expression of concern allows existing findings to remain accessible, while giving readers a chance to form their own judgement.

Lastly, pathogens carried by cells (either intentionally or accidentally) or in components of the culture medium are potential health hazards, and laboratory-acquired viral infections have been reported.6-8 Indeed, the stakes are higher when cells are to be introduced into patients, highlighting the critical importance of quality control in cell therapies.

While pipetting is a key part of everyday laboratory work, it is also one of the stages most prone to contamination. As sample contamination can affect the reliability of results, it is important to know how it can be avoided, saving both time and money. Download this poster for ten tips to avoiding contamination in pipetting.

Avoid leaving your cultures out of the incubator for extended periods

Label all cultures clearly and unambiguously

Disinfect work surfaces before and after use

Check disinfectants are effective and appropriate choices for the job

Work with only one cell culture at a time

Use separate media and reagents for each individual cell line

Quarantine new cell lines until tested negative for mycoplasma

Avoid overusing and relying on antibiotics

Record how long a cell line has been kept in cultureThe design of the laboratory can also play a role; cabinets should be placed away from through-traffic, doors and air-conditioning inlets.6 Restricting area access to allow only essential laboratory personnel to enter reduces disturbances of airflow around the microbiological safety cabinet.

Water baths, CO2 incubators, shelves and water pans are common culprits and should be cleaned or autoclaved regularly, using a chemical disinfectant where appropriate. Other routes of infection include accidental spillages, contact with non-sterile surfaces, splash-back from pipetting or pouring, microscopic aerosol, and infestation by vertebrates, dust and mites.Research groups isolating stem cells use unique cell properties to filter out undesired cells, explains Dr Mei-Ju Hsu, postdoctoral researcher in stem cell therapy at Leipzig University. Dr Hsu notes that: one of the most important features of mesenchymal stem cells is the attachment and growth on the plastic surfaces without prior coating. This step serves as a good way to eliminate the non-adherent cells (e.g. blood cells) by the removal of supernatants.

Mycoplasma is one of the most common cell culture contaminants, with six species of mycoplasma accounting for 95% of all contamination. Therefore, it is important to improve our understanding of where mycoplasma contamination can stem from and how best to prevent it. Download this infographic to discover more about mycoplasma contamination in cell culture labs.

Go here to read the rest:
Meet the Culprits of Cell Culture Contamination - Technology Networks

What Will Be The Growth of Animal Stem Cell Therapy Market? Dagoretti News – Dagoretti News

Latest release from SMI with title Animal Stem Cell Therapy Market Research Report 2019-2026 (by Product Type, End-User / Application and Regions / Countries) provides an in-depth assessment of the Animal Stem Cell Therapy including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. Global Animal Stem Cell Therapy Market study with 100+ market data Tables, Pie Chat, Graphs & Figures is now released BY SMI. The report presents a complete assessment of the Market covering future trends, current growth factors, attentive opinions, facts, and industry-validated market data forecast until 2026.

Global Animal Stem Cell Therapy Market Segmentations

The segmentation chapter allows readers to understand aspects of the Global Animal Stem Cell Therapy Market such as products/services, available technologies, and applications. These chapters are written in a way that describes years of development and the process that will take place in the next few years. The research report also provides insightful information on new trends that are likely to define the progress of these segments over the next few years.

Download FREE Sample Report with Latest Industry Trends 2019 @ https://www.stratagemmarketinsights.com/sample/11599(**Note: Free Sample Copy Only with TOC, Graph, Charts)

Global Animal Stem Cell Therapy Market and Competitive Analysis

Know your current market situation! Not only an important element for new products but also for current products given the ever-changing market dynamics. The study allows marketers to stay in touch with current consumer trends and segments where they can face a rapid market share drop. Discover who you really compete against in the marketplace, with Market Share Analysis know market position, % market Share and Segmented Revenue of Animal Stem Cell Therapy Market

Segmentation and Targeting

Essential demographic, geographic, psychographic and behavioral information about business segments in the Animal Stem Cell Therapy market is targeted to aid in determining the features company should encompass in order to fit into the business requirements. For the Consumer-based market the study is also classified with Market Maker information in order to better understand who the clients are, their buying behavior and patterns.

*** For the global version, a list of below countries by region can be added as part of customization at minimum cost.North America (United States, Canada & Mexico)Asia-Pacific (Japan, China, India, Australia, etc)Europe (Germany, UK, France, etc)Central & South America (Brazil, Argentina, etc)Middle East & Africa (United Arab Emirates, Saudi Arabia, South Africa, etc)

Animal Stem Cell Therapy Product/Service Development

Knowing how the product/services fit the needs of clients and what changes would require to make the product more attractive is the need of an hour. Useful approaches to focus group by utilizing User Testing and User Experience Research. Demand-side analysis always helps to correlate consumer preferences with innovation.

Marketing Communication and Sales Channel

Understanding marketing effectiveness on a continual basis help determine the potential of advertising and marketing communications and allow us to use best practices to utilize an untapped audience. In order to make marketers make effective strategies and identify why the target market is not giving attention, we ensure the Study is Segmented with appropriate marketing & sales channels to identify potential market size by Revenue and Volume* (if Applicable).

Pricing and Forecast

Pricing/subscription always plays an important role in buying decisions; so we have analyzed pricing to determine how customers or businesses evaluate it not just in relation to other product offerings by competitors but also with immediate substitute products. In addition to future sales Separate Chapters on Cost Analysis, Labor*, production* and Capacity are Covered.

How geography and sales fit together

This study is helpful to all operators who want to identify the exact size of their target audience at a specific geographic location. Animal Stem Cell Therapy Market allows entrepreneurs to determine local markets for business expansion. This study answers the questions below:

1. Where do the requirements come from?2. Where do non-potential customers reside?3. What is the buying behavior of customers in a specific region?4. What is the spending power of the customers in a particular region?

** Enquire for customization in Report @ https://www.stratagemmarketinsights.com/quiry/11599

Having our reviews and subscribing our report will help you solve the subsequent issues:

*Uncertainty about the future: Our research and insights help our customers predict the upcoming revenue pockets and growth areas. This will guide customers to invest their resources.

*Understanding market sentiments: It is very important to have a fair understanding of market sentiment for your strategy. Our insights will help you see every single eye on market sentiment. We maintain this analysis by working with key opinion leaders on the value chain of each industry we track.

*Understanding the most reliable investment center: Our research evaluates investment centers in the market, taking into account future demand, profits, and returns. Clients can focus on the most prestigious investment centers through market research.

*Evaluating potential business partners: Our research and insights help our clients in identifying compatible business partners.

Furthermore, the years considered for the study are as follows:

Historical year 2013-2018Base year 2018Forecast period** 2019 to 2026 [** unless otherwise stated]

More Related Reports ajitk123

Read the original post:
What Will Be The Growth of Animal Stem Cell Therapy Market? Dagoretti News - Dagoretti News

Biobanks Market To Witness An Impressive Growth During The Forecast Period 2017 2025 Dagoretti News – Dagoretti News

The global Biobanks market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Biobanks market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Biobanks market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Biobanks market. The Biobanks market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2321&source=atm

Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market include BioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=2321&source=atm

The Biobanks market research covers an exhaustive analysis of the following data:

The Biobanks market research addresses critical questions, such as

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=2321&source=atm

The global Biobanks market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

Read the rest here:
Biobanks Market To Witness An Impressive Growth During The Forecast Period 2017 2025 Dagoretti News - Dagoretti News

Stem Cell Alopecia Treatment Market Booming by Size, Revenue, Trend and Top Growing Companies 2026 – Vital News 24

Stem Cell Alopecia Treatment Market

New Jersey, United States, The report offers an all-inclusive and accurate research study on the Stem Cell Alopecia Treatment Market while chiefly that specialize in current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly have the benefit of the thorough marketing research provided within the report. The authors of the report have compiled an in depth study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to induce a decent understanding of future development of the Stem Cell Alopecia Treatment market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to assist with comprehensive evaluation of the Stem Cell Alopecia Treatment market.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=15102&utm_source=VN24&utm_medium=002

Top 10 Companies in the Global Stem Cell Alopecia Treatment Market Research Report:

Global Stem Cell Alopecia Treatment Market: Competitive Landscape

The research analysts who have authored this report are experts in performing competitive analysis of the global Stem Cell Alopecia Treatment market. They have deeply profiled leading as well as other players of the global Stem Cell Alopecia Treatment market with large emphasis on their market share, recent developments, business overview, markets served, and growth strategies. The report not only provides valuable insights into the competitive landscape but also concentrates on minor as well as major factors influencing the business of players. The product portfolios of all companies profiled in the report are compared in quite some detail in the product analysis section.

Global Stem Cell Alopecia Treatment Market: Segment Analysis

The global Stem Cell Alopecia Treatment market is segmented according to type, application, and region. The analysts have carefully studied each segment and sub-segment to provide a broad segmental analysis of the global Stem Cell Alopecia Treatment market. The segmentation study identifies leading segments and explains key factors supporting their growth in the global Stem Cell Alopecia Treatment market. In the regional analysis section, the report authors have shown how different regions and countries are growing in the global Stem Cell Alopecia Treatment market and have predicted their market sizes for the next few years. The segmental analysis will help companies to focus on high-growth areas of the global Stem Cell Alopecia Treatment market.

Global Stem Cell Alopecia Treatment Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=VN24&utm_medium=002

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market, By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market, By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market, By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=VN24&utm_medium=002

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Read more:
Stem Cell Alopecia Treatment Market Booming by Size, Revenue, Trend and Top Growing Companies 2026 - Vital News 24

Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine – India Education Diary

New Delhi: On Saturday, January 18th, 2020, the Advancells Group & the International Fertility Center together ended their first workshop Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020). The three-day workshop had specialized doctors, medical practitioners, learned scientists of Advancells, the leaders in cell manufacturing & processes and IFC, one of Indias most prestigious Fertility institute who were joined by candidates with MBBS/BAMS/BHMS/BPharma & Masters degree in Life Sciences.

The key-note speaker of the workshop was Dr. Rita Bakshi, founder and chairperson of International Fertility Centre, the oldest fertility clinic and one of the most renowned IVF clinics in India, one of the organizers of the event. Participants also had a privilege to listen to Dr. Sachin Kadam, CTO, Advancells and gain hands-on experience in the preparation of PRP; Liposuction method; and Bone Marrow aspiration. All these techniques were talked about at length and demonstrated in the form of manual & kit-based models to help the candidates gain exposure.

Dr. Punit Prabha, Head of Clinical Research and Dr. Shradha Singh Gautam, Head of Lab Operations at Advancells successfully set the base of stem cell biology for the participants who were experts in gynecology field, stem cell research and pain specialist. With the help of detailed analysis of Application of PRP for Skin rejuvenation; Preparation of Micro-fragmented Adipose Tissue and Nano Fat & SVF (Stromal Vascular Fraction) from Adipose Tissue; and Cell Culturing and Expansion in a Laboratory, applicants understood the application of stem cells in aesthetics, cosmetology, and anti-aging.

Vipul Jain, Founder & CEO of Advancells Group said, Educating young scientists about stem cells is important for us. With this workshop we wanted to discuss and share the challenges and lessons we have learned in our journey of curing our customers. We wanted to establish more concrete knowledge base in the presence of subject matter experts and help our attendees in more possible ways. We are hopeful to have successfully achieved what we claimed with this workshop.

Given the resounding success of the Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020), its hoped that the future events shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

Advancells Group Advancells is leading the field of stem cell therapies in India and abroad, with representative offices in Bangladesh and Australia. The company provides arrangements for stem cell banking and protocols for partner doctors and hospitals which they can use for treating the patients using regenerative medicine. With a GMP compliant research and processing center that works on different cell lines from various sources such as Bone Marrow, Adipose Tissue, Dental Pulp, Blood, Cord Tissue etc. Advancells also intends to file a patent for this processing technology soon.

For more information, visit https://www.advancells.com/

International Fertility Centre IFC is Indias leading fertility center under the leadership and guidance of Dr. Rita Bakshi. She along with her solid team of experienced doctors have create a network of 10+ IVF clinics located in India and Nepal. Their services include In-vitro Fertilization (IVF), Intrauterine Insemination (IUI), Intracytoplasmic Injection (ICSI), Egg Donation, Surrogacy, Blastocyst, Assisted Hatching, Hysteroscopy, Laparoscopy and much more.

Read the rest here:
Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - India Education Diary

Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 – Fusion Science Academy

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Phase Change Materials (PCM) Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Phase Change Materials (PCM) market. We have also provided absolute dollar opportunity and other types of market analysis on the global Phase Change Materials (PCM) market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Phase Change Materials (PCM) market. All findings and data on the global Phase Change Materials (PCM) market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Phase Change Materials (PCM) market available in different regions and countries.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2591133&source=atm

The authors of the report have segmented the global Phase Change Materials (PCM) market as per product, application, and region. Segments of the global Phase Change Materials (PCM) market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Phase Change Materials (PCM) market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Phase Change Materials (PCM) in these regions, from 2014 to 2025, coveringNorth America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Turkey etc.)Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)South America (Brazil etc.)Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market includeBASFHoneywellCryopakEntropy SolutionsClimator SwedenPhase Change Energy SolutionsOutlast TechnologiesDow Building SolutionsChemours CompanyPCM EnergyRubitherm TechnologiesBy the product type, the market is primarily split intoOrganicInorganicBio-based

By the end users/application, this report covers the following segmentsBuilding & ConstructionRefrigerationConsumer GoodsOthers

We can also provide the customized separate regional or country-level reports, for the following regions:North AmericaUnited StatesCanadaMexicoAsia-PacificChinaJapanSouth KoreaIndiaAustraliaIndonesiaThailandMalaysiaPhilippinesVietnamEuropeGermanyFranceUKItalyRussiaCentral & South AmericaBrazilMiddle East & AfricaTurkeyGCC CountriesEgyptSouth Africa

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2591133&source=atm

Phase Change Materials (PCM) Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Phase Change Materials (PCM) Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Phase Change Materials (PCM) Market in South, America region is also expected to grow in near future.

The Phase Change Materials (PCM) Market report highlights is as follows:

This Phase Change Materials (PCM) market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Phase Change Materials (PCM) Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Phase Change Materials (PCM) Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Phase Change Materials (PCM) Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2591133&licType=S&source=atm

Read the original post:
Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 - Fusion Science Academy

The Center for Breakthrough Medicines is Building the World’s Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO)…

KING OF PRUSSIA, Pa., Jan. 22, 2020 /PRNewswire/--The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a Contract Development and Manufacturing Organization (CDMO) and specialty investment company, to alleviate the critical lack of capacity that is preventing patients from accessing critically needed cell and gene therapies. The CDMO is occupying over 40 percent of The Discovery Labs' 1.6 million square foot biotech, healthcare and life sciences campus in King of Prussia, PA.

The CDMO provides preclinical through commercial manufacturing of cell and gene therapies and component raw materials. It offers process development, plasmid DNA,viral vectors, cell banking, cell processing, and support testing capabilities all under one roof. The immense $1.1 billion facility will provide instant capacity as the largest known single source for accelerating the delivery and affordability of lifesaving and life-changing therapies from the bench to the patient's bedside.

The Company has initiated a substantial hiring effort targeting the best and brightest of the life sciences community including, experts in CGMP manufacturing. The Company expects to hire over 2,000 team members within the next 30 months.

The CDMO has retained Nucleus Careers, a cloud-based specialty life sciences human capital recruiting and retention management expert, to buildout the entire team. Nucleus has proprietary recruiting and retention software designed for large scale human capital buildouts of high growth companies.

In addition to developing the world's largest single-point cell and gene therapy manufacturing facility, The Discovery Labs is establishing THE COLONY which will provide custom built discovery labs, breakthrough funding, sponsored research agreements, housing and relocation for the world's leading iconic experts in cell and gene therapy.

THE COLONY will seek to work hand in hand with scientists from both academic and pharmaceutical institutions to unlock and expedite groundbreaking therapies.

Marco A. Chacn, Ph.D., Founder of Paragon Bioservices and Chairman of The Discovery Labs states, "musicians, artists, members of religious communities and great thinkers throughout time have formed colonies where freedom of thought and expression combined with unlimited dreams and potential have resulted in the world's greatest accomplishments." Dr. Chacn went on to say, "the goal of THE COLONY is to unshackle the potential of the world's greatest scientific minds."

The ability for the industry's greatest scientists to cohabitate, collaborate, cooperate, and communicate via technology and in person will create an exponential therapeutic "X FACTOR." THE COLONY seeks to unlock institutional barriers prohibiting the world's greatest scientists from moving at a pace necessary in today's ever-changing therapeutic revolution. THE COLONY will partner with the institutions where the scientists currently work by providing equity, license fees, and revenue sharing.

"The Center for Breakthrough Medicines will be serving companies from the earliest stages through commercialization. Its exceptional scale and offering will quickly relieve the production bottleneck for advanced therapies by reducing the time, complexity, and cost of commercializing vitally needed gene and cell therapies," noted Audrey Greenberg, Board Member and Executive Managing Director for The Discovery Labs.

The addition of this end-to-end manufacturing capability is expected to significantly enhance the offerings of The Discovery Labs in an area that has become one of the largest life sciences hubs in the world. Renovations are underway to construct a total of 86 plasmid, viral vector production, universal cell processing, CGMP testing, process development and cell banking suites. The viral vector and cell processing suites will be fully compliant with both U.S. Food and Drug Administration and European Medicines Agency standards. All suites will offer the flexibility to meet client-specific workflows and will be able to adapt quickly to meet demand. The Company is in the process of reserving capacity now for late 2020.

"Today brilliant scientists are advancing an unprecedented number of gene and cell therapy drug candidates. The real tragedy, however, is a scarcity of manufacturing know-how, which is complex and expensive," said Alex Karnal, Partner and Managing Director of Deerfield Management and a Board Member of the Discovery Labs. "With its visionary business model, it is hoped that The Center for Breakthrough Medicines will help realize the promise of cell and gene therapies in time to treat the many patients who need them."

The Discovery Labs provides a central campus where the world's greatest scientists can collaborate on new therapeutic discoveries to eradicate diseases affecting small and large segments of the global population. The Center for Breakthrough Medicines will work with these leaders, life sciences companies, large pharmaceutical companies, and academic and government institutions.

This new manufacturing capability is a transformational addition to The Discovery Labs market offering and dovetails with The Discovery Labs biotech incubator, Unite IQ. Unite IQ offers immediate space to emerging life sciences companies and scientists giving them the ability to grow from startup to enterprise company on one campus. The incubator and accelerator space at Unite IQ provides a comprehensive home for startups with every resource needed to initiate business operations. Unite IQ tenants are expected to utilize the discovery, development, testing, and manufacturing capabilities of the Center for Breakthrough Medicines with seamless forward integration of processes and analytics, and seamless tech transfer from research lab to large scale production

The Emerging Field of Cell and Gene Therapy in Pennsylvania

The demand for clinical and commercial manufacturing capacity is acute and expected to remain that way. The current shortfall in manufacturing for cell and gene therapies is severely underserved with few approved products. There are currently approximately 1,100 advanced therapies in the pipeline pending FDA approval. This will greatly increase highly skilled manufacturing demand. Dr. Peter Marks, Director of the FDA Center for Biologics Evaluation and Research, states, "what keeps me up at night is will we be able to manufacture these on a scale that will allow us to bring the benefit of these therapies to patients?"He further added that "if we can help see cost of goods and ability to manufacture reproducibly improve, I think that'll be a big thing."All of this adds up to a supply constrained market that The Center for Breakthrough Medicines aims to help address.

With the potential to treat and even cure disabling, and deadly diseases, gene and cell therapies are ushering in a new era of medicine. These therapies may eventually be able to cure genetic conditions, such as cystic fibrosis, hemophilia A, and a range of cancers. The Philadelphia area has become the epicenter for the flourishing field of gene and cell therapy. Research from CBRE currently ranks the market among the top biotech clusters for medical research and health services. The cluster has become known worldwide as "Cellicon Valley"for its leadership in research and development of this rapidly evolving field. The Discovery Lab's suburban Philadelphia location offers a talent rich environment due to the area's preponderance of large pharmaceutical companies and the Philadelphia region's position boasting the top 10 universities and primary school systems in nation.

Over the past three years, multiple Philadelphia companies have received approvals for major breakthroughs in cell and gene therapy. In 2017, the U.S. FDA approved the first-ever CAR-T cell therapy, Novartis's Kymriah, which originated at the University of Pennsylvania. Shortly thereafter, the FDA gave landmark approval for the first-ever gene therapy to treat a genetic blindness condition to Spark Therapeutics, a start-up founded by researchers at Children's Hospital of Philadelphia. These discoveries and others in the pipeline are attracting billions of dollars of venture capital. The Greater Philadelphia Region set a recent record in venture capital financing.

The Discovery Labs Center for Breakthrough Medicines joins more than 25 healthcare, life sciences and tech-enabled companies that already call The Discovery Labs King of Prussia home.

Brian O'Neill, Founder of The Discovery Labs Center for Breakthrough Medicines, and Tony Khoury, Board Member of The Discovery Labs and Engineer at Project Pharma, will be speaking at the 2020 PhacilitateWorld Stem Cell Summit discussing The Future of Gene Therapy Manufacturing at 4 p.m. today at the Hyatt Regency in Miami, Florida.

Contact Audrey Greenberg at agreenberg@thediscoverylabs.com for more information about development services, manufacturing capacity, incubator space or leasing information at the property.

About The Discovery LabsPart of MLP Ventures, The Discovery Labs is a global provider of world-class cGMP manufacturing, turnkey laboratory solutions, critical materials and office space that support therapeutic products and services to the biotechnology and pharmaceutical industry so that groundbreaking medicines get to the patients that need them. The location in eastern King of Prussia is a prototype for a global rollout of The Discovery Labs, providing Big Pharma, emerging life sciences, consumer and technology companies flexible, end-to-end technical real estate and business infrastructure for the customer's entire lifecycle from discovery to delivery, including manufacturing capacity. It is the first fully integrated environment that merges technology and life sciences under one roof to drive innovation.

About Deerfield Management

Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy.

Media Contact:Tony DeFazio, DeFazio Communications(o) 484-534-3306 (c) 484-410-1354tony@defaziocommunications.com

SOURCE The Discovery Labs

The Discovery Labs

The rest is here:
The Center for Breakthrough Medicines is Building the World's Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO)...

Toxys Strengthens Leadership Team with Appointment of CBO and COO Positions – BioSpace

LEIDEN, The Netherlands, January 21, 2020 /B3C newswire/ --Today,Toxysannounces the appointment of a Chief Business Officer (CBO) and a Chief Operating Officer (COO). Toxys BV is a biotech company based in Leiden, The Netherlands, that provides innovative, high-fidelityin vitrotoxicity screening solutions to identify carcinogenic and other hazardous properties of compounds for the pharmaceutical, chemical, cosmetics and food industries. With this strengthened leadership, Toxys will further accelerate business growth to become an industry-leader in animal-free chemical safety testing.

Paula van Rossumis promoted toCBO. Paula joined Toxys in 2016 as Director Business Development & Sales and has been instrumental for the business growth of Toxys. Paula holds a MSc degree from Leiden University in Biomedical Sciences and Science-based Business.

Remco Derris promoted toCOO. Remco joined Toxys in 2014 as lab manager and product specialist. He has been instrumental for management of all commercial toxicity screening as well operational management of the R&D laboratory. Remco holds a MSc degree from Leiden University in Biomedical Sciences.

Paula and Remco are valuable additions to the senior Toxys Management Team. Their proven experience and expertise in business development, sales, customer relations and lab management will further boost the growth of Toxyssaid Giel Hendriks, CEO of Toxys BV.

Link to the press release

Tweet this press release

AboutToxysToxys is a Dutch biotech companythat offers a broad spectrum of innovativein vitrotoxicology solutions. Toxys was founded in 2014 as a spin-off from the Leiden University Medical Center and has its state-of-the-art laboratory facilities located at the Leiden BioScience Park. We are experts in the field of genetic and developmental toxicology with a focus on Mode-of-Action. We are dedicated to bringing relevant information to our clients on potential human health hazards of novel and existing drugs, chemicals and other substances. Toxys is currently working with 7 of the Top10 global Pharma companies and several major chemical, cosmetics and food multinationals.

Toxys has developed the unique ToxTracker and ReproTracker assays. ToxTracker is a high-throughput stem cell-based reporter suite of assays that allows reliable identification of genotoxic carcinogens. ToxTracker provides mechanistic insight into undesired properties of chemicals. ReproTracker is currently under development and its commercial launch (planned for early 2020) will allowin vitrodevelopmental toxicity hazard identification. These assays can be particularly useful in Mode-of-Action and Adverse Outcome Pathway (AOP) approaches for chemical safety assessment.

We offer ToxTracker and ReproTracker as tailored service to our customers, often in combination with standard toxicology assays or under license and as kits for use in partners own laboratories. Toxys is highly valued for its scientific expertise, high quality results and responsiveness.

Contact

Giel HendriksCEO+31 71 3322474g.hendriks@toxys.com

Media Contact

Paula van RossumCBO+31 71 3322470p.vanrossum@toxys.com

Keywords: Humans; Carcinogens; Chemical Safety; Cosmetics; Carcinogenesis; Industry; Food Industry; DNA Damage; Drug-Related Side Effects and Adverse Reactions; Mutagenicity Tests; Biotechnology

The rest is here:
Toxys Strengthens Leadership Team with Appointment of CBO and COO Positions - BioSpace